Table 2.
Effects of the simplified and traditional treatment regimens on drug resistance.
| Study name | Mutation site | Description | ||
|---|---|---|---|---|
| RAL | PIs/r | NRTIs | ||
| Kozal et al. (2012) | Q148R/Q, T97T/A, N155H | Not given | Not given | Of the patients who failed antiretroviral therapy: 36.3% (4/11) of patients were found to have an RAL-resistant mutation; 9.1% (1/11) of patients developed phenotypic resistance to RAL without any evidence of an RAL-drug-resistant mutation; No patient had ATV or NRTI resistance (genotypic or phenotypic). |
| Reynes et al. (2011) | G163R, N155H, T97A | Not given | M184V, N155H | 3.96% (4/101) LPV/r + RAL and 2.86% LPV/r + TDF/FTC (3/105) met the criteria for resistance testing of virologic failure. |
| Paton et al. (2014) | 143R, 155H, and 140S+148H | 82A, 46I and 76V | 70R, 67N, and 65R | In the patients who failed antiretroviral therapy, there was intermediate- or high-level resistance in 2% of patients in the NRTI group and 1% in the RAL group. |
| Amin et al. (2015) | Not given | Not given | Not given | Not given |
| Group et al. (2013) | T66A, T143A/T143C/T143H, A 155H | Not given | M184V, 69 insertion complex 151 insertion complex |
Of the patients who failed antiretroviral therapy, RAL and NRTI resistance was found in 14.9% and 14.0% of patients, respectively. No PI mutations were recorded. |
| La Rosa et al. (2016) | T66A, T97A, T143C/A, A155H | M46I, L76V, V82A | M184V, TAMS, T69A | 13.3% (6/50) of participants showed NRTI-resistant mutations; 15.56% (7/50) of participants showed PI-resistant mutations; 26.09% (12/46) of participants showed RAL-resistant mutations |
| Raffi et al. (2014) | A155H | Not given | L65A | Of the patients who failed antiretroviral therapy, 17.2% (5/29) had resistance to integrase, and 3.4% (1/29) had resistance to NRTI. |
| Hakim et al. (2018) | Y143R, N155H, Q148H, T97A, | 46I/L54V, | 70R, 67N, 215Y, 41L, TAM1, 151M | 3% (10/321) of participants (viral loads <1000 copies/mL) showed NRTI-resistant mutations 2% (7/321) of participants (viral loads <1000 copies/mL) showed PI-resistant mutations; 7% (10/321) of participants (viral loads <1000 copies/mL) showed RAL-resistant mutations |
RAL, raltegravir. NRTI, nucleoside or nucleotide reverse transcriptase inhibitor. PIs/r, ritonavir-boosted protease inhibitor.